Klor-Con Powder for oral solution is available as packets that contain 1.5g of potassium chloride (supplying potassium 20mEq and chloride 20mEq) in 30- and 100-count cartons.
Initially, the patient experienced no complications. But approximately 12 hours following therapy, he awoke with shortness of breath and functional quadriplegia.
The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the label for Veltassa (patiromer; Relypsa) for oral suspension.
Nephcentric announced the launch of Ure-Na (urea), a new medical food for the management of euvolemic and hypervolemic hyponatremia, including syndrome of inappropriate ADH secretion (SIADH).
Hospira announced a voluntary recall of one lot of Sodium Bicarbonate Injection 8.4%, USP, due to particulate presence within a single-dose glass fliptop vial from a confirmed complaint.
Long-distance triathletes who drink too much water during competition may end up with hyponatremia, according to a letter to the editor published in the March 10 issue of the New England Journal of Medicine.
Cumberland announced the publication of data from a multicenter, open-label study that further supports the use of Vaprisol (conivaptan) Injection.
Lupin announced that it has received final approval from the Food and Drug Administration (FDA) for its Potassium Chloride Extended Release Capsules, a generic version of Actavis' Potassium Chloride Extended Release Capsules.
Baxter announced a voluntary recall of 2 lots of 0.9% Sodium Chloride Injection, 250mL Viaflex Plastic Container and 70% Dextrose Injection, 2000mL, due to potential presence of particulate matter.
VistaPharm announced the launch of Potassium Chloride Solution, 10% in Unit Dose. The unit dose version of the only approved Potassium Chloride oral solution.
Relypsa announced that the Food and Drug Administration (FDA) has approved Veltassa (patiromer) for oral suspension, indicated for the treatment of hyperkalemia.
Baxter announced a voluntary recall of two lots of 0.9% Sodium Chloride intravenous (IV) solutions due to potential particulate matter.
Patiromer oral suspension, an investigational drug, was found to reduce elevated potassium levels in patients with chronic diabetic kidney disease in a study published in JAMA.
Hospira has announced a voluntary recall of one lot of Lactated Ringer's Irrigation 3000mL following a confirmed customer report of several dark, fibrous particulate floating within the solution of the primary container.
Hospira announced a voluntary recall of one lot of 0.9% Sodium Chloride Injection due to particulate matter sealed in the bag at the additive port area. The particulate matter was identified as a human hair.
Baxter announced that the Food and Drug Administration (FDA) has approved Phoxillum Renal Replacement Solutions (BK4/2.5 and B2K4/0) for use in continuous renal replacement therapy (CRRT) to replace plasma volume removed by ultrafiltration, correct electrolyte and acid-base imbalances, and for use in drug poisoning when CRRT is used to remove dialyzable substances.
For patients with hyperkalemia, sodium zirconium cyclosilicate (ZS-9) and patiromer show promise for reducing potassium levels, according to two new studies.
Baxter announced a voluntary recall of one lot of Highly Concentrated Potassium Chloride Injection 10mEq/100mL at the user level due to a complaint of mislabeling of the overpouch.
Hyponatremia can be a potentially dangerous side effect of certain antidepressant medications based on antidepressant class.
For patients undergoing pancreaticoduodenectomy (PD), fluid restrictions with 3% hypertonic saline can significantly cut complication rates.
Baxter announced that the FDA has approved Flexbumin (albumin [human]) 5% solution for the treatment of hypovolemia, hypoalbuminemia due to general causes, burns, and for use during cardiopulmonary bypass surgery as a component of the pump prime.
Hospira announced a voluntary nationwide recall of one lot of Lactated Ringers and 5% Dextrose Injection, USP, 1000mL, Flexible Container.
Hispanics became much more likely to take their heart medicines after Medicare's prescription drug benefit plan was launched in 2006, but there was only a small increase seen among black patients.
Par announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Potassium Chloride Extended-Release (ER) Capsules.
The USPSTF has found that insufficient evidence to evaluate the benefits and harms of multivitamins and most single- or paired-nutrient supplements for the prevention of cardiovascular disease and cancer.
Quality, patient outcomes, and costs must all be assessed in determining the appropriateness of noninvasive cardiovascular imaging.
Getting to the Heart of the Matter: A Review of Potential Drug Interactions With Cardiac Medications
Cardiac drug interactions make up almost 25% of all preventable adverse drug reactions.